Literature DB >> 7933076

Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes.

G Laux1, F Dugrillon, C Eckert, B Adam, U Zimber-Strobl, G W Bornkamm.   

Abstract

Epstein-Barr virus (EBV) transforms resting B cells in vitro very efficiently. The nuclear viral protein EBV nuclear antigen 2 (EBNA2) is absolutely required for this process and also acts as a transcriptional activator of cellular and viral genes. As shown previously, EBNA2 transactivates the promoters of the viral latent membrane proteins. It interacts indirectly with an EBNA2-responsive cis element of the terminal protein 1 (TP1) promoter. To identify the sequences mediating EBNA2 transactivation of the bidirectional promoter region driving expression of the latent membrane proteins LMP and TP2 in opposite directions, we assayed the effects of EBNA2 on the activities of promoter deletion and site-directed mutants of TP2 and LMP promoter luciferase reporter gene constructs by cotransfections into EBNA2-negative Burkitt's lymphoma cells. We were able to delineate an 80-bp EBNA2-responsive region (EBNA2RE) between -232 and -152 relative to the LMP RNA start site which could also mediate EBNA2-dependent activation on a heterologous promoter. Sequences of 20 and 32 bp located at the 5' and 3' ends, respectively, of the EBNA2RE were both essential for EBNA2 responsiveness. Full transactivation of the LMP and TP2 promoters seemed to require 20 bp of 5' adjacent sequences in addition to the 80-bp element. Electrophoretic mobility shift assays revealed specific protein-DNA complexes formed at the EBNA2RE. Oligonucleotides from -181 to -152 and -166 to -132 relative to the LMP RNA start site visualized one B-cell and one B-cell-plus-HL60-specific retarded protein-DNA complex, respectively. Additionally, an oligonucleotide from -253 to -210 revealed two specific protein-DNA complexes with nuclear extracts from different B and non-B cells, suggesting also the binding of ubiquitously expressed proteins on the EBNA2RE. Thus, these experiments defined a 80-bp cis element sufficient for conferring EBNA2 inducibility and demonstrated specific interactions of cellular proteins at DNA sequences within the EBNA2RE, which are critical for transactivation by EBNA2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7933076      PMCID: PMC237131     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene.

Authors:  U Zimber-Strobl; K O Suentzenich; G Laux; D Eick; M Cordier; A Calender; M Billaud; G M Lenoir; G W Bornkamm
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

2.  Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation.

Authors:  J I Cohen; F Wang; E Kieff
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

3.  EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus.

Authors:  N S Sung; S Kenney; D Gutsch; J S Pagano
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element.

Authors:  R Fåhraeus; A Jansson; A Ricksten; A Sjöblom; L Rymo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein.

Authors:  F Liu; M R Green
Journal:  Cell       Date:  1990-06-29       Impact factor: 41.582

6.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.

Authors:  F Wang; C Gregory; C Sample; M Rowe; D Liebowitz; R Murray; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

7.  Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.

Authors:  F Wang; S F Tsang; M G Kurilla; J I Cohen; E Kieff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

8.  Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5'-flanking region.

Authors:  L F Hu; J Minarovits; S L Cao; B Contreras-Salazar; L Rymo; K Falk; G Klein; I Ernberg
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  Early events in Epstein-Barr virus infection of human B lymphocytes.

Authors:  C Alfieri; M Birkenbach; E Kieff
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

10.  Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line.

Authors:  W King; A L Thomas-Powell; N Raab-Traub; M Hawke; E Kieff
Journal:  J Virol       Date:  1980-11       Impact factor: 5.103

View more
  44 in total

1.  A role for SKIP in EBNA2 activation of CBF1-repressed promoters.

Authors:  S Zhou; M Fujimuro; J J Hsieh; L Chen; S D Hayward
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus.

Authors:  D Salamon; M Takacs; D Ujvari; J Uhlig; H Wolf; J Minarovits; H H Niller
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  C-terminal domain of the Epstein-Barr virus LMP2A membrane protein contains a clustering signal.

Authors:  L Matskova; I Ernberg; T Pawson; G Winberg
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Epstein-Barr virus nuclear antigen 2 binds via its methylated arginine-glycine repeat to the survival motor neuron protein.

Authors:  Stephanie Barth; Michael Liss; Marc D Voss; Thomas Dobner; Utz Fischer; Gunter Meister; Friedrich A Grässer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  JC virus promoter/enhancers contain TATA box-associated Spi-B-binding sites that support early viral gene expression in primary astrocytes.

Authors:  Leslie J Marshall; Lisa D Moore; Matthew M Mirsky; Eugene O Major
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

6.  Differential hyperacetylation of histones H3 and H4 upon promoter-specific recruitment of EBNA2 in Epstein-Barr virus chromatin.

Authors:  Nathalie Alazard; Henri Gruffat; Edwige Hiriart; Alain Sergeant; Evelyne Manet
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

7.  CKII site in Epstein-Barr virus nuclear protein 2 controls binding to hSNF5/Ini1 and is important for growth transformation.

Authors:  Bogaslaw Kwiatkowski; Szu Yu Jenny Chen; William H Schubach
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance.

Authors:  Alexey V Gordadze; Chisaroka W Onunwor; RongSheng Peng; David Poston; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  A somatic knockout of CBF1 in a human B-cell line reveals that induction of CD21 and CCR7 by EBNA-2 is strictly CBF1 dependent and that downregulation of immunoglobulin M is partially CBF1 independent.

Authors:  Sabine Maier; Maja Santak; Anja Mantik; Kristina Grabusic; Elisabeth Kremmer; Wolfgang Hammerschmidt; Bettina Kempkes
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

10.  Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2.

Authors:  Walter Lucchesi; Gareth Brady; Oliver Dittrich-Breiholz; Michael Kracht; Rainer Russ; Paul J Farrell
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.